Lung cancer is the most often diagnosed kind of cancer, and it is growing quickly around the world.
In 2022, lung cancer constituted 12.4 percent of all cancer cases globally. In second and third place, respectively, were breast cancer (11.6 percent) and colon cancer (9.6 percent).
18.7% of cancer-related fatalities were due to lung cancer, with 9.3% coming from colon cancer, 7.8% from liver cancer, and 6.9% from breast cancer. However, the world's first mRNA vaccination trial for lung cancer therapy is about to begin.
A phase I human clinical study for the vaccine, known as BNT116, is now taking place in 34 research facilities across the US, UK, Germany, Hungary, Poland, Spain, and Turkey. The vaccine was created by BioNTech.
By specifically targeting and eliminating the malignant cells, this vaccination stops the illness from returning. The clinical study will enroll 130 patients with lung cancer in its initial phase. This vaccine is similar to the Covid-19 vaccinations in that it employs messenger RNA.
In order to help the immune system combat the malignant cells, the vaccination acquaints it with certain aspects of the tumor. Experts say that the vaccine's goal is to boost a patient's immune system against cancer without harming healthy cells.
According to him, this vaccine, which targets certain antigens on cancer cells, is based on mRNA technology, which will be crucial for the treatment of cancer. The vaccine will be given to clinical trial participants once a week for a duration of six weeks.
After then, for a total of 54 weeks, one dose of the vaccination will be given every three weeks. In other words, the timeline for the second and third stages will be disclosed following the release of the clinical trial's results, which should be known by the end of 2019 or the beginning of 2026.
0 Comments